Published
July 27, 2026
This settlement resolves investor claims that ChemoCentryx misled the market about its vasculitis drug avacopan and its FDA dealings. If you bought or acquired ChemoCentryx (CCXI) common stock between November 26, 2019 and May 6, 2021, you can claim a share of a $69,000,000 fund — but you need your brokerage records, and the deadline is October 1, 2026.
Current Status
Claims are open. The deadline to submit a Claim Form online or to have a mailed form postmarked is October 1, 2026; the notice states the date without a timezone, so treat the date itself as the cutoff. The court granted preliminary approval on June 12, 2026, and the Settlement Hearing on final approval is scheduled for October 29, 2026 at 2:00 p.m. Pacific time by Zoom videoconference — rescheduled from October 22, 2026, and still subject to change without further notice. No final approval order has been entered, and no payment date has been announced. Payments will be made only after the court approves the settlement and a plan of allocation, after any appeals are resolved, and after all claims are processed.
Status
Claims Open
Claim Deadline
October 1, 2026
Submitted online or postmarked by this date · no timezone specified in the notice
Estimated Payout
$2.88 per share
Estimated average recovery before court-approved fees and expenses, which are estimated at $0.84 per share · pro rata by recognized loss · $69,000,000 fund
Proof Required
Yes
Trade confirmations, account statements, or a broker letter documenting every Class Period transaction plus the May 7 – August 4, 2021 look-back period
What Changed Recently?
The dollar figure on this settlement nearly doubled, and the reason is unusual enough to be worth understanding before you file.The parties signed a Memorandum of Understanding on January 26, 2026 agreeing in principle to settle for $35,000,000, and the class representative moved for preliminary approval of that deal on March 13, 2026. On April 27, 2026, while that motion was pending, the FDA's Center for Drug Evaluation and Research filed a public notice proposing the withdrawal of TAVNEOS (avacopan) — the drug at the center of the case. The parties went back to the table and, on May 15, 2026, signed a revised stipulation for $69,000,000 in cash, which supersedes and voids the original $35,000,000 settlement. The court preliminarily approved the revised settlement on June 12, 2026.
Also worth knowing: at the time the settlement was reached, the investors had already lost. On August 15, 2025 the district court granted the defendants' motion for summary judgment and entered judgment against the class, finding the alleged misrepresentations were not actionable because they were statements of opinion or were not misleading. The class representative appealed to the Ninth Circuit and filed its opening brief on January 5, 2026; the settlement was negotiated while that appeal was pending. Class counsel's stated reason for settling is that without a reversal on appeal and a subsequent win at trial, the class would recover nothing at all.
The defendants deny every allegation and deny any violation of the federal securities laws. They state they are settling solely to eliminate the risk, burden, and expense of continued litigation, and the settlement may not be construed as an admission of wrongdoing.
What Is the Case About?
ChemoCentryx was a biopharmaceutical company whose common stock traded on the NASDAQ under the ticker CCXI until October 19, 2022. The lawsuit alleged that ChemoCentryx and its former President and CEO made material misrepresentations about the safety and efficacy of its vasculitis drug avacopan — specifically concerning the ADVOCATE study, the drug's Phase 3 clinical trial — and about the company's communications with the FDA regarding avacopan's approval.The complaint asserted claims under Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, and additional claims against the former CEO under Sections 20(a) and 20A. The Section 20A claim alleged he sold ChemoCentryx stock while in possession of material non-public information about avacopan, and that class members bought stock contemporaneously with those sales. The class representative alleged the statements inflated the stock price and that investors were damaged when the market later learned what had allegedly been concealed. All of this remains an allegation — the district court granted summary judgment to the defendants, and no court has found any violation.
Who Qualifies?
The class was certified by court order on March 6, 2024 and consists of all persons who purchased or otherwise acquired ChemoCentryx common stock between November 26, 2019 and May 6, 2021, inclusive, and were damaged thereby.The only eligible security is ChemoCentryx common stock (NASDAQ: CCXI, CUSIP 16383L106). Option contracts are not eligible, although stock acquired by exercising an option counts, using the option's exercise date and exercise price.
Excluded are the defendants, their successors and assigns, the past and current executive officers and directors of the defendants, the immediate family members of the individual defendant, and the legal representatives, heirs, successors, or assigns of any excluded person, along with any entity in which an excluded person has or had a direct or controlling ownership interest. Also excluded are anyone who requested exclusion during the earlier class-notice process — though those investors can opt back in, as described below.
One eligibility point catches people out: receiving the notice does not make you a class member, and being a class member does not guarantee a payment. Under the proposed Plan of Allocation you generally need to have held your Class Period shares through at least the close of trading on May 3, 2021 to have any recognized loss. Shares bought during the Class Period and sold before that point have a Recognized Loss Amount of $0.00.
How Much Can You Get?
The settlement fund is $69,000,000 in cash. The class representative's damages expert estimates that, if every class member participates, the average recovery would be approximately $2.88 per eligible share before deductions. That is an estimate only, and your own recovery depends on when you bought and sold, at what prices, and on how many valid claims are filed. Some class members will recover more, some less.Deductions come out of the fund before distribution: taxes, notice and administration costs, litigation expenses (class counsel will request up to $5 million), and attorneys' fees (class counsel will request up to 22% of the fund). If the court awards what is requested, the notice estimates the average cost at approximately $0.84 per affected share. Class members are not personally liable for any of these fees.
What remains — the Net Settlement Fund — is distributed pro rata based on the relative size of each authorized claimant's Recognized Claim. The Plan of Allocation calculates recognized loss from the estimated artificial inflation in the share price on your purchase and sale dates, using a per-day inflation table that runs from $22.03 to $38.07 per share across most of the Class Period and drops to $16.57 and $17.10 on May 4 and May 5, 2021. Purchases matched to sales use First In, First Out (FIFO) ordering. Recognized loss on short sales and the purchases covering them is zero.
Two limits are worth flagging. First, the PSLRA 90-day look-back cap applies: recognized losses are reduced using ChemoCentryx's closing prices from May 7 through August 4, 2021, a period whose mean closing price was $12.85. Second, if your overall Class Period trading produced a market gain rather than a loss, your Recognized Claim is zero — and if your market loss is smaller than your calculated Recognized Claim, the claim is capped at the market loss. Finally, if your calculated distribution comes to less than $10.00, no check is issued and those funds go to claimants receiving $10.00 or more.
What Proof Is Required?
This is a documentation-heavy claim, which is normal for securities settlements and is the single most common reason claims get rejected.You must submit genuine and sufficient documentation for every transaction and holding you list: copies of trade confirmations, account statements, or an authorized statement from your broker or financial institution containing the same transactional and holding information. Neither the parties nor the claims administrator has any record of your trades.
Specifically, the Claim Form asks for your holdings as of the opening of trading on November 26, 2019; every purchase or acquisition from November 26, 2019 through the close of trading on May 6, 2021; total purchases from May 7 through August 4, 2021; every sale from November 26, 2019 through the close of trading on August 4, 2021; and your holdings as of the close of trading on August 4, 2021. That post-Class-Period window is the PSLRA look-back period, and you have to report it even though shares bought then are not themselves eligible. Failing to report all transaction and holding information for the requested periods may result in rejection of your claim.
File one Claim Form per separate legal entity or separately managed account — an individual should not combine IRA transactions with transactions held in their own name. Claimants with a large number of transactions can request the electronic filing format from the claims administrator through the official website.
Can You Opt Out? What About Objecting?
You cannot exclude yourself now. Because the class was certified back in March 2024 and class members already had an exclusion window that closed January 14, 2025, the court exercised its discretion not to allow a second opportunity to opt out.If you did exclude yourself earlier and now want in, you can opt back into the class by submitting a written Request to Opt Back Into the Class to the claims administrator so that it is received no later than September 21, 2026. It must state your name and contact information, state that you request to opt back into the class in this case, and be signed by you or an authorized representative. Opting back in does not by itself get you paid — you still have to file a Claim Form by October 1, 2026.
Any class member may object to the settlement, the Plan of Allocation, or the fee and expense request. A written objection must identify the case name and number, include your full name, the basis for your belief that you are a class member, the basis of your objection, and your signature, and it must be filed with or postmarked to the court on or before September 21, 2026. Class counsel's fee and expense motion will be filed by September 10, 2026 and posted on the official settlement website, so you can read it before the objection deadline. If you also want to speak at the hearing, you must file a notice of intention to appear so it is received by September 21, 2026.
What Is the Deadline?
The Claim Form and supporting documentation must be submitted online, or postmarked if mailed, no later than October 1, 2026. The notice gives the date without a timezone. Objections, notices of intention to appear, and requests to opt back into the class are all due September 21, 2026. A class member who misses the claim deadline is barred from receiving any payment but remains bound by the settlement and its release.How Do You Take Action?
File online at the official settlement website, ChemoCentryx Securities Litigation.com, where the Claim Form, the full Settlement Notice, the stipulation, the court documents, and the electronic filing template are all posted. A paper Claim Form can be downloaded from the same site and mailed to the claims administrator at the address printed on the form.Before you start, pull your brokerage records for the whole span from November 26, 2019 through August 4, 2021. Do not highlight anything on the form or the supporting documents, do not send originals, and keep copies of everything. The claims administrator acknowledges receipt of a Claim Form by mail within 60 days — your claim is not considered filed until you get that acknowledgment, so follow up through the official website if it does not arrive.
What Happens Next?
The next milestone is the Settlement Hearing on October 29, 2026 at 2:00 p.m. Pacific time before the U.S. District Court for the Northern District of California, by Zoom videoconference. At that hearing the court will consider whether the settlement is fair, reasonable, and adequate, whether to enter judgment dismissing the action, whether to approve the Plan of Allocation, and whether to grant class counsel's fee and expense motion. Class members do not need to attend, and the date and time can change without further written notice — the official settlement website posts any change.If the court grants final approval, distribution still waits for any appeals to be resolved and for all claims to be processed, which takes a substantial amount of time. No payment date has been announced. Roughly six months after the initial distribution, any money left over may be re-distributed to claimants who cashed their checks, if class counsel and the administrator determine that is cost-effective; whatever ultimately cannot be cost-effectively distributed goes to the Bluhm Legal Clinic Complex Civil Litigation and Investor Protection Center at the Northwestern Pritzker School of Law.
Sources and Verification
• Official Settlement Website — ChemoCentryx Securities Litigation• Notice of (I) Proposed Class Action Settlement; (II) Settlement Hearing; and (III) Motion for Attorneys' Fees and Litigation Expenses, dated July 2, 2026, including Appendix A (Plan of Allocation), Table A (artificial inflation) and Table B (90-day look-back)
• Proof of Claim and Release Form, ChemoCentryx Securities Litigation
• Homyk v. ChemoCentryx, Inc., Master File No. 4:21-cv-03343-JST and related case No. 4:21-cv-04357, U.S. District Court for the Northern District of California, Oakland Division
OpenClassActions.com is a consumer news site and is not the claims administrator or a law firm.
Questions
Why did the settlement amount go from $35 million to $69 million?
The parties first agreed in principle to a $35,000,000 settlement in January 2026 and filed for preliminary approval on March 13, 2026. On April 27, 2026, the FDA's Center for Drug Evaluation and Research filed a public notice proposing the withdrawal of TAVNEOS (avacopan). The parties then negotiated further and, on May 15, 2026, signed a revised stipulation for $69,000,000, which supersedes and voids the original $35,000,000 settlement.
I sold my ChemoCentryx shares before May 2021. Do I get anything?
Under the proposed Plan of Allocation, shares purchased during the Class Period but sold before the close of trading on May 3, 2021 have a Recognized Loss Amount of $0.00. To have a Recognized Loss Amount you generally must have held Class Period shares through at least the close of trading on May 3, 2021, and shares bought on May 4 or May 5, 2021 must have been held through at least the close of trading on May 5, 2021.
Can I exclude myself from this settlement?
No. The class was certified in March 2024 and class members already had an opportunity to request exclusion, with a deadline of January 14, 2025. The Court exercised its discretion not to allow a second exclusion opportunity in connection with the settlement. If you previously excluded yourself, you may opt back into the class by submitting a written request that is received by September 21, 2026, and you would then also need to file a Claim Form by October 1, 2026.
Do options or shares held in a retirement plan count?
Option contracts are not eligible securities. Only ChemoCentryx common stock counts, though stock acquired by exercising an option is eligible, using the exercise date and exercise price. Participants in an ERISA-covered retirement or benefit plan should not include shares held through that plan on their own Claim Form; claims based on the plan's holdings may be made by the plan's trustees.
What is the minimum payment from the ChemoCentryx settlement?
If an authorized claimant's calculated distribution comes to less than $10.00, no distribution is made to that claimant and those funds are included in the distribution to claimants whose amount is $10.00 or more.
Related Securities Settlements
If you track pharmaceutical securities cases, the closest open comparison is the Amylyx Pharmaceuticals settlement, which also turns on statements about a drug's clinical results and has an August 31, 2026 deadline. Other open claim windows include the Estée Lauder settlement and the Stitch Fix settlement. Every open and expired case we track is listed on the securities class actions hub.
For more class actions keep scrolling below.
Settlement Amount
$69,000,000
Case Title
Homyk v. ChemoCentryx, Inc.
Case Number
4:21-cv-03343-JST
Related case No. 4:21-cv-04357
Court
U.S. District Court, Northern District of California
Settlement Hearing
October 29, 2026 at 2:00 PM Pacific
By Zoom videoconference · rescheduled from October 22, 2026
Administrator
Kroll Settlement Administration
Official Website
ChemoCentryx Securities Litigation.com
